These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 28963086)

  • 1. Developing an exogenous pulmonary surfactant-glucocorticoids association: Effect of corticoid concentration on the biophysical properties of the surfactant.
    Cimato A; Facorro G; Martínez Sarrasague M
    Respir Physiol Neurobiol; 2018 Jan; 247():80-86. PubMed ID: 28963086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the structure and surfactant activity of novel formulations containing exogenous pulmonary surfactant and glucocorticoids.
    Cimato A; Hoyos Obando A; Facorro G; Martínez Sarrasague M
    Respir Physiol Neurobiol; 2016 Nov; 233():33-40. PubMed ID: 27476933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of cholesterol and budesonide on biophysical properties of clinical surfactant.
    Zhang H; Wang YE; Neal CR; Zuo YY
    Pediatr Res; 2012 Apr; 71(4 Pt 1):316-23. PubMed ID: 22391630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budesonide associated with exogenous pulmonary surfactant in a novel formulation to improve the delivery to the lung.
    Cimato A; Facorro G; Martínez Sarrasague M
    Respir Physiol Neurobiol; 2022 Feb; 296():103825. PubMed ID: 34808585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biophysical and chemical stability of surfactant/budesonide and the pulmonary distribution following intra-tracheal administration.
    Chen CM; Chang CH; Chao CH; Wang MH; Yeh TF
    Drug Deliv; 2019 Dec; 26(1):604-611. PubMed ID: 31204848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biophysical inhibition of synthetic vs. naturally-derived pulmonary surfactant preparations by polymeric nanoparticles.
    Beck-Broichsitter M; Ruppert C; Schmehl T; Günther A; Seeger W
    Biochim Biophys Acta; 2014 Jan; 1838(1 Pt B):474-81. PubMed ID: 24184425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determining the fluid ordered and disordered phases in a pulmonary surfactant by electron spin resonance technique.
    Cimato A; Facorro G; Martínez Sarrasague M
    Respir Physiol Neurobiol; 2020 Jan; 271():103309. PubMed ID: 31561012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of budesonide and salbutamol on surfactant properties.
    Palmer D; Schürch S; Belik J
    J Appl Physiol (1985); 2000 Sep; 89(3):884-90. PubMed ID: 10956330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biophysical activity of animal-derived exogenous surfactants mixed with rifampicin.
    Kolomaznik M; Calkovska A; Herting E; Stichtenoth G
    Adv Exp Med Biol; 2015; 839():31-9. PubMed ID: 25252905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyaluronan decreases surfactant inactivation in vitro.
    Lu KW; Goerke J; Clements JA; Taeusch HW
    Pediatr Res; 2005 Feb; 57(2):237-41. PubMed ID: 15585679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structures of pulmonary surfactant films adsorbed to an air-liquid interface in vitro.
    Bachofen H; Gerber U; Gehr P; Amrein M; Schürch S
    Biochim Biophys Acta; 2005 Dec; 1720(1-2):59-72. PubMed ID: 16405864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and surface activity of diether-linked phosphoglycerols: potential applications for exogenous lung surfactants.
    Notter RH; Wang Z; Wang Z; Davy JA; Schwan AL
    Bioorg Med Chem Lett; 2007 Jan; 17(1):113-7. PubMed ID: 17055273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multilayers at the surface of solutions of exogenous lung surfactant: direct observation by neutron reflection.
    Follows D; Tiberg F; Thomas RK; Larsson M
    Biochim Biophys Acta; 2007 Feb; 1768(2):228-35. PubMed ID: 17156743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-ionic surfactant vesicles in pulmonary glucocorticoid delivery: characterization and interaction with human lung fibroblasts.
    Marianecci C; Paolino D; Celia C; Fresta M; Carafa M; Alhaique F
    J Control Release; 2010 Oct; 147(1):127-35. PubMed ID: 20603167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biophysical activity of an artificial surfactant containing an analogue of surfactant protein (SP)-C and native SP-B.
    Palmblad M; Johansson J; Robertson B; Curstedt T
    Biochem J; 1999 Apr; 339 ( Pt 2)(Pt 2):381-6. PubMed ID: 10191270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of serum proteins on an exogenous pulmonary surfactant: ESR analysis of structural changes and their relation with surfactant activity.
    Martínez Sarrasague M; Cimato A; Rubin de Celis E; Facorro G
    Respir Physiol Neurobiol; 2012 Jul; 183(1):48-57. PubMed ID: 22683782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of dynamic surface properties of therapeutic surfactants and lung phospholipids.
    Banerjee R; Puniyani RR; Bellare JR
    J Biomater Appl; 2000 Oct; 15(2):140-59. PubMed ID: 11081642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Keeping lung surfactant where it belongs: protein regulation of two-dimensional viscosity.
    Alonso C; Waring A; Zasadzinski JA
    Biophys J; 2005 Jul; 89(1):266-73. PubMed ID: 15833995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of captive and pulsating bubble surfactometers with use of lung surfactants.
    Putz G; Goerke J; Taeusch HW; Clements JA
    J Appl Physiol (1985); 1994 Apr; 76(4):1425-31. PubMed ID: 8045815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amphotericin B and pulmonary surfactant.
    Griese M; Schams A; Lohmeier KP
    Eur J Med Res; 1998 Aug; 3(8):383-6. PubMed ID: 9707520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.